LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 268 of 535
Next
>>
>
6676 to 6700 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
MDA-MB-231			uM	LJP5	3	N22	72	hr	1235	4983	4929	1.0109	1.0109
MDA-MB-231			uM	LJP5	3	N23	72	hr	1235	4756	4929	0.9649	0.9645
MDA-MB-231			uM	LJP5	3	N24	72	hr	1235	4830	4929	0.9799	0.9797
BT-20	Seliciclib	0.04	uM	LJP5	1	J06	72	hr	1097	3907	3735	1.0460	1.0515
BT-20	Seliciclib	0.04	uM	LJP5	2	J06	72	hr	1097	3989	3877	1.0287	1.0313
BT-20	Seliciclib	0.04	uM	LJP5	3	J06	72	hr	1097	3831	3925	0.9759	0.9737
BT-20	Seliciclib	0.12	uM	LJP5	1	J05	72	hr	1097	3770	3735	1.0093	1.0105
BT-20	Seliciclib	0.12	uM	LJP5	2	J05	72	hr	1097	4166	3877	1.0743	1.0803
BT-20	Seliciclib	0.12	uM	LJP5	3	J05	72	hr	1097	3583	3925	0.9128	0.9032
BT-20	Seliciclib	0.37	uM	LJP5	1	J04	72	hr	1097	3345	3735	0.8955	0.8790
BT-20	Seliciclib	0.37	uM	LJP5	2	J04	72	hr	1097	3488	3877	0.8995	0.8870
BT-20	Seliciclib	0.37	uM	LJP5	3	J04	72	hr	1097	3488	3925	0.8886	0.8756
BT-20	Seliciclib	1.11	uM	LJP5	1	J03	72	hr	1097	3254	3735	0.8712	0.8499
BT-20	Seliciclib	1.11	uM	LJP5	2	J03	72	hr	1097	2937	3877	0.7574	0.7170
BT-20	Seliciclib	1.11	uM	LJP5	3	J03	72	hr	1097	3054	3925	0.7780	0.7448
BT-20	Seliciclib	3.33	uM	LJP5	1	J02	72	hr	1097	2731	3735	0.7312	0.6753
BT-20	Seliciclib	3.33	uM	LJP5	2	J02	72	hr	1097	3060	3877	0.7891	0.7561
BT-20	Seliciclib	3.33	uM	LJP5	3	J02	72	hr	1097	2711	3925	0.6906	0.6354
BT-20	Seliciclib	10	uM	LJP5	1	J01	72	hr	1097	1597	3735	0.4276	0.2366
BT-20	Seliciclib	10	uM	LJP5	2	J01	72	hr	1097	1705	3877	0.4397	0.2738
BT-20	Seliciclib	10	uM	LJP5	3	J01	72	hr	1097	1616	3925	0.4117	0.2343
BT-20	AT-7519	0.04	uM	LJP6	1	K06	72	hr	1097	3009	3610	0.8334	0.7987
BT-20	AT-7519	0.04	uM	LJP6	2	K06	72	hr	1097	3058	3713	0.8234	0.7909
BT-20	AT-7519	0.04	uM	LJP6	3	K06	72	hr	1097	3011	3696	0.8146	0.7791
BT-20	AT-7519	0.12	uM	LJP6	1	K05	72	hr	1097	1761	3610	0.4877	0.3169

|<
<<
Previous
Page 268 of 535
Next
>>
>
6676 to 6700 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)